Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.43 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | PDE8B | O95263 | 1/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6651633 | 0.80 | OPRM1 (0.48) | OPRM1OPRL1ALDH1A1MAPK1ACE | |
| SCHEMBL6651630 | 0.80 | OPRM1 (0.48) | OPRM1OPRL1ALDH1A1MAPK1ACE | |
| SCHEMBL14135549 | 0.78 | OPRM1 (0.49) | OPRM1OPRL1ALDH1A1MAPK1KDM4E | |
| SCHEMBL13155623 | 0.78 | OPRM1 (0.49) | OPRM1OPRL1ALDH1A1MAPK1KDM4E | |
| SCHEMBL13452979 | 0.78 | OPRM1 (0.49) | OPRM1OPRL1ALDH1A1MAPK1KDM4E | |
| SCHEMBL14559363 | 0.77 | MTNR1A (0.52) | OPRM1ALDH1A1MAPK1 | |
| SCHEMBL29401750 | 0.77 | OPRD1 (0.49) | MAPK1ACENR1D1 | |
| SCHEMBL5064869 | 0.77 | OPRD1 (0.49) | MAPK1ACENR1D1 | |
| SCHEMBL29163531 | 0.77 | OPRD1 (0.49) | MAPK1ACENR1D1 | |
| SCHEMBL4595926 | 0.77 | OPRD1 (0.49) | MAPK1ACENR1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071329-A1 | METHODS FOR IDENTIFYING COMPOUNDS OF INTEREST USING ENCODED LIBRARIES | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110251089-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | GLAXOSMITHKLINE (US) | 2011-10-13 | — | — | US | disclosed |
| US-7989395-B2 | Methods for identifying compounds of interest using encoded libraries | GLAXOSMITHKLINE LLC (US) | 2011-08-02 | — | — | US | disclosed |
| EP-2338990-A2 | Methods for synthesis of encoded libraries | Praecis Pharmaceuticals Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251089-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | RNGTT, DTYMK, DUT | OPRM1 3104/4885OPRL1 1341/4885ALDH1A1 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.